Nemolizumab for treating atopic dermatitis and prurigo nodularis


featured image

Nemolizumab is currently in development for atopic dermatitis and prurigo nodularis. Atopic dermatitis is the most common form of eczema, a long-term (chronic) condition that causes patches of the skin to become itchy, dry and cracked.

Interventions: Nemolizumab
Therapeutic Areas: Dermatology
Year: 2022

Nemolizumab is currently in development for atopic dermatitis and prurigo nodularis. Atopic dermatitis is the most common form of eczema, a long-term (chronic) condition that causes patches of the skin to become itchy, dry and cracked. In moderate-to-severe cases, the patches cover a large area of the skin and can be associated with an intense itch. Prurigo nodularis is a chronic skin disorder characterised by the presence of hard, extremely itchy bumps known as nodules. Although the cause of the condition is unknown, the nodules are the result of persistent, intense scratching and rubbing of the skin. Current treatment options for atopic dermatitis and prurigo nodularis have varied effectiveness, and can cause side-effects. Therefore, there is a need to develop additional treatment options for these patients.